Extending support to the Government of Indias action for price caps of medical devices starting from stents to protect consumers has been actively welcomed by AIMED – Association of Indian Medical Devices industry, the apex body representing domestic medical devices manufacturers; other consumer groups; and Indian manufacturers.
Drug-Eluting Stents (DES) – Overall Overview
- Were launched in 2001 by the US multinational with more than 85% share until 2010 when Indian DES started getting acceptability
- Command a higher price as is popularly considered of better quality standards due to the clinical trials performed
Indian Drug-Eluting Stents (DES) – Overview
- Current Indian Market is around 5.50 lakh stents per annum out of which more than 90% are DES.
- Has witnessed growth at a speed of around 15% every year
- Will become the second largest market after China by 2020
- Indian DES have proven equivalent to & even better than American DES on both clinical performance & quality standards
- The Indian companies like Translumina and Meril have huge capacities and have already achieved close to 20% market share within 5 years of their launch.
Key Takeaways
- Will bring relief for many poor patients for whom the cost of affording a drug-eluting stent had become prohibitive
- Will ensure fair practices in this important sector
- Will break industry-doctor nexus that strengthened due to lack of awareness
- Will increase transparency in terms of pricing of DES
- Will encourage rational use of stents with proper due diligence on the treatment method
Representatives of the multinational companies importing such devices – Key Objections
- Will discourage innovation
- Will deny access to quality products from abroad
Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video
